Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis
Background/Aims: Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear. Methods: PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, Clinical...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Cell Physiol Biochem Press GmbH & Co KG
2016-11-01
|
Series: | Cellular Physiology and Biochemistry |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/452551 |
id |
doaj-bfc350962ede4ec6a208b532c9559d5d |
---|---|
record_format |
Article |
spelling |
doaj-bfc350962ede4ec6a208b532c9559d5d2020-11-25T02:40:09ZengCell Physiol Biochem Press GmbH & Co KGCellular Physiology and Biochemistry1015-89871421-97782016-11-01401-236136910.1159/000452551452551Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-AnalysisMingyi ZhouPing YuJinglei QuYing ChenYang ZhouLingyu FuJingdong ZhangBackground/Aims: Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear. Methods: PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and the American Society of Clinical Oncology and European Society for Medical Oncology databases were searched to identify abstracts for randomized controlled trials (RCTs) evaluating the efficacy of bevacizumab for the first-line treatment of patients with RAS mutations mCRC from inception to the end of April 2016. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were estimated. Results: Ten eligible papers reporting six RCTs were included. In the network meta-analysis of patients with RAS mutations, bevacizumab + chemotherapy prolonged PFS compared with chemotherapy alone (HR 0.75, 95% CI 0.51-1.10), but the difference was not statistically significant. Bevacizumab + chemotherapy did not prolong OS compared with chemotherapy alone (HR 1.10, 95% CI 0.73-1.66). Conclusion: There was insufficient evidence to definitively state that patients with RAS mutations mCRC could benefit from bevacizumab combined with chemotherapy as first-line treatment.http://www.karger.com/Article/FullText/452551RAS mutationsNetwork meta-analysisMetastatic colorectal cancerFirst line treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mingyi Zhou Ping Yu Jinglei Qu Ying Chen Yang Zhou Lingyu Fu Jingdong Zhang |
spellingShingle |
Mingyi Zhou Ping Yu Jinglei Qu Ying Chen Yang Zhou Lingyu Fu Jingdong Zhang Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis Cellular Physiology and Biochemistry RAS mutations Network meta-analysis Metastatic colorectal cancer First line treatment |
author_facet |
Mingyi Zhou Ping Yu Jinglei Qu Ying Chen Yang Zhou Lingyu Fu Jingdong Zhang |
author_sort |
Mingyi Zhou |
title |
Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis |
title_short |
Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis |
title_full |
Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis |
title_fullStr |
Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis |
title_full_unstemmed |
Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis |
title_sort |
efficacy of bevacizumab in the first-line treatment of patients with ras mutations metastatic colorectal cancer: a systematic review and network meta-analysis |
publisher |
Cell Physiol Biochem Press GmbH & Co KG |
series |
Cellular Physiology and Biochemistry |
issn |
1015-8987 1421-9778 |
publishDate |
2016-11-01 |
description |
Background/Aims: Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear. Methods: PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and the American Society of Clinical Oncology and European Society for Medical Oncology databases were searched to identify abstracts for randomized controlled trials (RCTs) evaluating the efficacy of bevacizumab for the first-line treatment of patients with RAS mutations mCRC from inception to the end of April 2016. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were estimated. Results: Ten eligible papers reporting six RCTs were included. In the network meta-analysis of patients with RAS mutations, bevacizumab + chemotherapy prolonged PFS compared with chemotherapy alone (HR 0.75, 95% CI 0.51-1.10), but the difference was not statistically significant. Bevacizumab + chemotherapy did not prolong OS compared with chemotherapy alone (HR 1.10, 95% CI 0.73-1.66). Conclusion: There was insufficient evidence to definitively state that patients with RAS mutations mCRC could benefit from bevacizumab combined with chemotherapy as first-line treatment. |
topic |
RAS mutations Network meta-analysis Metastatic colorectal cancer First line treatment |
url |
http://www.karger.com/Article/FullText/452551 |
work_keys_str_mv |
AT mingyizhou efficacyofbevacizumabinthefirstlinetreatmentofpatientswithrasmutationsmetastaticcolorectalcancerasystematicreviewandnetworkmetaanalysis AT pingyu efficacyofbevacizumabinthefirstlinetreatmentofpatientswithrasmutationsmetastaticcolorectalcancerasystematicreviewandnetworkmetaanalysis AT jingleiqu efficacyofbevacizumabinthefirstlinetreatmentofpatientswithrasmutationsmetastaticcolorectalcancerasystematicreviewandnetworkmetaanalysis AT yingchen efficacyofbevacizumabinthefirstlinetreatmentofpatientswithrasmutationsmetastaticcolorectalcancerasystematicreviewandnetworkmetaanalysis AT yangzhou efficacyofbevacizumabinthefirstlinetreatmentofpatientswithrasmutationsmetastaticcolorectalcancerasystematicreviewandnetworkmetaanalysis AT lingyufu efficacyofbevacizumabinthefirstlinetreatmentofpatientswithrasmutationsmetastaticcolorectalcancerasystematicreviewandnetworkmetaanalysis AT jingdongzhang efficacyofbevacizumabinthefirstlinetreatmentofpatientswithrasmutationsmetastaticcolorectalcancerasystematicreviewandnetworkmetaanalysis |
_version_ |
1724782805448130560 |